Pancreatic Cancer Screening of High-Risk Individuals in Arkansas
Status: | Active, not recruiting |
---|---|
Conditions: | Colorectal Cancer, Skin Cancer, Cancer, Other Indications, Cardiology, Gastrointestinal, Gastrointestinal, Dermatology |
Therapuetic Areas: | Cardiology / Vascular Diseases, Dermatology / Plastic Surgery, Gastroenterology, Oncology, Other |
Healthy: | No |
Age Range: | 18 - 99 |
Updated: | 6/27/2018 |
Start Date: | November 2015 |
End Date: | November 2026 |
100 subjects who have a family history of pancreatic cancer (PC), or known genetic syndromes
associated with increased risk of pancreatic cancer, will be followed for five years. This
data will be used to determine the pancreatic cancer and precancerous lesion detection rate
in High Risk Individuals (HRIs). Subjects may agree to annual imaging and annual biomarkers
or to biomarkers only.
associated with increased risk of pancreatic cancer, will be followed for five years. This
data will be used to determine the pancreatic cancer and precancerous lesion detection rate
in High Risk Individuals (HRIs). Subjects may agree to annual imaging and annual biomarkers
or to biomarkers only.
Inclusion Criteria:
- Have a family history of PC as listed below or who have one of the following
syndromes: Peutz-Jeghers syndrome - STK11; BRCA 1 and 2; PALB2; ATM; FAMMM / P16;
HNPCC (Lynch) / MMR genes; Hereditary pancreatitis - PRSS1
- Individuals with three or more affected blood relatives (1st, 2nd or 3rd degree)
- Individuals with two or more affected blood relatives with PC, with at least one
affected FDR, should be considered for screening.
- Patients with a history of Peutz-Jeghers syndrome should be screened, regardless of
family history of PC.
- Patients with a known p16 (FAMMM syndrome) with one affected 1st or 2nd degree
relative will be considered for screening.
- Patients with a known BRCA1 or BRCA2 mutation with one affected 1st or 2nd degree
relative should be considered for screening.
- Patients with a known PALB2 mutation with one affected family member should be
considered for screening.
- Patients with a known Mismatch-repair gene-mutation carriers (Lynch syndrome) with one
affected family member should be considered for screening.
Exclusion Criteria:
- Not candidates for surgery
We found this trial at
1
site
529 West Markham Street
Little Rock, Arkansas 72205
Little Rock, Arkansas 72205
(501) 686-7000
Phone: 501-526-4020
University of Arkansas for Medical Sciences The University of Arkansas for Medical Sciences (UAMS) in...
Click here to add this to my saved trials